

12th January 2022

Attention:

Ms Michaels
SHPA

RE. NOTIFICATION OF OUT OF STOCK PERIOD FOR YERVOY (IPILIMUMAB) 200MG/40ML VIAL CONCENTRATE SOLUTION FOR INTRAVENOUS INFUSION

Dear Ms Michaels,

On behalf of Bristol-Myers Squibb Australia Pty Ltd (BMS) I am writing to inform you that:

- From the end of January 2022 (anticipated, week commencing 24 January 2022), the Yervoy (Ipilimumab) 200mg vial/40mL vial concentrate solution for intravenous infusion will be out of stock in Australia and not available. This situation is anticipated to last 3-4 weeks.

We are working to resolve this matter as soon as possible. BMS knows the importance of a steady and reliable supply of critical medicines for patients and remains committed to delivering this medicine to patients who need it.

Please note, supply of Yervoy (Ipilimumab) 50mg/10mL vial concentrate for intravenous infusion is not impacted at this time. However, we will closely monitor supply and let you know if this should change.

BMS have notified the Therapeutics Goods Administration (TGA) of this supply shortage.

If you could please disseminate this information to the COSA members, it would be greatly appreciated.

Product Details

BMS Code	BMS Product	Anticipated	Resolved supply
1279684	YERVOY SINJ 200MG (1VLX40ML) AU/NZ	Week commencing 24 January 2022	Late February 2022

If you have any questions relating to the shortage, please contact the BMS Medical Information Department at 1800 067 567 or via email at: medinfo.australia@bms.com.

Yours sincerely,



Melinda Munns

Medical Director
Bristol-Myers Squibb Australia